NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined company, based on the... Read More

First data in NPC1 on treatment in this age group over a period of 48 weeks At 24 weeks of the sub-study, 7 of 8 patients (87%) and at 48 weeks of the sub-study, 6 of 7 patients (86%) show stabilization or improvement in Clinical Global Impression – Change (CGI-C) Scale Data presented at the 21 st Annual WORLDSymposium™ 2025 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in... Read More

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) to be highlighted in an oral presentation GAINESVILLE, Fla. / Jan 14, 2025 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and... Read More

NEWARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the first quarter of fiscal year 2025 ended October 31, 2024. “We anticipate proceeding to a shareholder vote on our pending merger agreement with Cyclo Therapeutics, Inc. (Nasdaq: CYTH) in the first calendar quarter of 2025 and closing promptly post shareholder approvals. Upon closing of the merger,... Read More

Strategic merger with Rafael Holdings to combine two companies and advance Trappsol ® Cyclo™ for NPC1 patients expected to close Q4 2024 Company on track for topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ in H1 2025 Submission of New Drug Application (NDA) to the Food and Drug Administration (FDA) and Marketing Authorization Application (MAA) to European Medicines Agency (EMA)... Read More

Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Trappsol ® Cyclo™ demonstrated to be... Read More

Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. & GAINESVILLE, Fla. / Aug 22, 2024 / Business Wire / Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that... Read More

Quarter marked by achievement of landmark milestone with completion of enrollment in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 GAINESVILLE, Fla. / Aug 15, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo... Read More

GAINESVILLE, Fla. / Jul 29, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a notice from the European Patent Office of a decision to grant European patent... Read More

GAINESVILLE, Fla. / Jun 25, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that two abstracts have been accepted for poster presentation at the SSIEM Annual Symposium 2024 being held... Read More

TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline data from the 48-week interim analysis of 104 enrolled patients is anticipated for H1 2025 If 48-week data demonstrate significance, submission of New Drug Application (NDA) to the Food and Drug Administration (FDA)... Read More

Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025 GAINESVILLE, Fla. / May 16, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company... Read More

Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ® Cyclo™ with FDA to enable a patient population lacking available therapies to have earlier access to a potentially efficacious product with an acceptable safety... Read More

GAINESVILLE, Fla. / Mar 14, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, “ Methods for... Read More

Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments Increased ownership in Day Three Labs to a majority interest of 79% NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024. “During... Read More

GAINESVILLE, Fla. / Jan 29, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO)... Read More

Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations GAINESVILLE, Fla. / Dec 27, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company... Read More

Ongoing pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) FDA feedback provides direction for the comparative interim analysis With aligned strategy, interim analysis data readout is anticipated for Q1 2025 FDA and Cyclo Therapeutics to meet in the first half of 2024 for pre-NDA meeting GAINESVILLE, Fla. / Dec 18, 2023 / Business Wire / Cyclo... Read More

NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023. “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the potential to generate value for our stockholders. We believe our strong balance... Read More

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) to be highlighted in a platform presentation GAINESVILLE, Fla. / Nov 21, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited... Read More

Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) Merger with Applied Molecular Transport, Inc. (“AMT”) on track to close before year end Company continues to bolster cash position to extend runway through clinical and regulatory milestones GAINESVILLE, Fla. / Nov 15, 2023 / Business Wire / Cyclo Therapeutics, Inc.... Read More

Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised) GAINESVILLE, Fla. / Oct 23, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced... Read More

Live webcast presentation on Thursday, October 12 th at 12:00 PM ET GAINESVILLE, Fla. / Oct 05, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer... Read More

Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations into 2H 2024 Upcoming milestones include completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top line data and preparation for NDA submission... Read More

Continued strong enrollment of pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) on track to complete enrollment by year end 2023 Company anticipates achieving 60% of enrollment of TransportNPC™ by end of August Topline results from TransportNPC™ expected Q4 2024 GAINESVILLE, Fla. / Aug 15, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo... Read More

GAINESVILLE, Fla. / Aug 02, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for... Read More

Data published in official journal of Molecular Genetics and Metabolism Reports: Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion Trappsol ® Cyclo™ was detected in the CSF Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS) Improvement in Scale Assessment and Rating of Ataxia (SARA)... Read More

NEWARK, N.J., June 13, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter of fiscal 2023 for the three months ended April 30, 2023, as well as the nine months ended April 30, 2023. “We continue to seek to expand our portfolio through strategic investments in companies with near term value inflection points which have the potential to generate value for our... Read More

GAINESVILLE, Fla. / Jun 12, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Communication from the European Patent Office (EPO) regarding Cyclo Therapeutics’... Read More

GAINESVILLE, Fla. / Jun 05, 2023 / Business Wire / Cyclo Therapeutics, Inc . (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a binding agreement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) under which Rafael... Read More

Company on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023 GAINESVILLE, Fla. / May 15, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and... Read More

GAINESVILLE, Fla. / May 02, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the... Read More

GAINESVILLE, Fla. / Apr 21, 2023 / Business Wire / C yclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed a private placement of its securities priced at-the-market under Nasdaq rules, with a group of... Read More

GAINESVILLE, Fla. / Mar 20, 2023 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2022 and provided a business update. “We continue to be extremely active... Read More

Continued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to complete enrollment by year end 2023 Patient enrollment and dosing in Phase 2b study of Trappsol ® Cyclo™ for the treatment of early Alzheimer’s Disease (AD) underway Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics”... Read More

Live video webcast on Thursday, January 19 th at 11:00 AM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor... Read More

Biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer’s disease, including cholesterol accumulation in regions of the brain, elevated levels of Tau in CSF, and amyloid plaques in the brain, bolsters rationale for studying Trappsol ® Cyclo™ for the treatment of early Alzheimer’s disease Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage... Read More

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of 2,608,696 shares of common stock (or common stock equivalents) at a... Read More

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstract has been accepted for poster presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting being held March 18 - 21, 2023, in... Read More

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 2,608,696 shares of common stock (or common stock equivalents) at a... Read More